Cholecystokinin and Schizophrenia
- 1 January 1986
- book chapter
- Published by Elsevier
- Vol. 65, 237-258
- https://doi.org/10.1016/s0079-6123(08)60654-8
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- Ontogeny of molecular forms of CCK-peptides in rat brain and gutLife Sciences, 1984
- Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disordersLife Sciences, 1984
- The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of ratNeuroscience Letters, 1984
- Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the ratNeuroscience Letters, 1983
- Immunological evidence of cholecystokinin-39 in porcine brainLife Sciences, 1983
- Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesionsLife Sciences, 1983
- The influence of vasoactive intestinal polypeptide and cholecystokinin of prolactin release in rat and human monolayer culturesLife Sciences, 1981
- Influence of cholecystokinin octapeptide sulfate ester on brain monoamine metabolism in ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Release of cholecystokinin peptides from a synaptosome-enriched fraction of rat cerebral cortexLife Sciences, 1979
- Naloxone-induced reversal of schizophrenic hallucinationsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1977